Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Mitochondria-dependent phase separation of disease-relevant proteins drives pathological features of age-related macular degeneration
Nilsa La Cunza, … , Kimberly A. Toops, Aparna Lakkaraju
Nilsa La Cunza, … , Kimberly A. Toops, Aparna Lakkaraju
Published April 6, 2021
Citation Information: JCI Insight. 2021;6(9):e142254. https://doi.org/10.1172/jci.insight.142254.
View: Text | PDF
Research Article Ophthalmology

Mitochondria-dependent phase separation of disease-relevant proteins drives pathological features of age-related macular degeneration

  • Text
  • PDF
Abstract

Age-related macular degeneration (AMD) damages the retinal pigment epithelium (RPE), the tissue that safeguards photoreceptor health, leading to irreversible vision loss. Polymorphisms in cholesterol and complement genes are implicated in AMD, yet mechanisms linking risk variants to RPE injury remain unclear. We sought to determine how allelic variants in the apolipoprotein E cholesterol transporter modulate RPE homeostasis and function. Using live-cell imaging, we show that inefficient cholesterol transport by the AMD risk-associated ApoE2 increases RPE ceramide, leading to autophagic defects and complement-mediated mitochondrial damage. Mitochondrial injury drives redox state–sensitive cysteine-mediated phase separation of ApoE2, forming biomolecular condensates that could nucleate drusen. The protective ApoE4 isoform lacks these cysteines and is resistant to phase separation and condensate formation. In Abca–/– Stargardt macular degeneration mice, mitochondrial dysfunction induces liquid-liquid phase separation of p62/SQSTM1, a multifunctional protein that regulates autophagy. Drugs that decrease RPE cholesterol or ceramide prevent mitochondrial injury and phase separation in vitro and in vivo. In AMD donor RPE, mitochondrial fragmentation correlates with ApoE and p62 condensates. Our studies demonstrate that major AMD genetic and biological risk pathways converge upon RPE mitochondria, and identify mitochondrial stress-mediated protein phase separation as an important pathogenic mechanism and promising therapeutic target in AMD.

Authors

Nilsa La Cunza, Li Xuan Tan, Thushara Thamban, Colin J. Germer, Gurugirijha Rathnasamy, Kimberly A. Toops, Aparna Lakkaraju

×

Figure 2

ApoE2 aggravates autophagic defects induced by lipofuscin bisretinoids.

Options: View larger image (or click on image) Download as PowerPoint
ApoE2 aggravates autophagic defects induced by lipofuscin bisretinoids.
...
(A) Stills from spots and tracks analyses of live imaging of EGFP-LC3 autophagosome trafficking in mock-transfected RPE or RPE expressing mCherry-tagged ApoE2, ApoE3, or ApoE4 treated with or without A2E. (B) Average number of EGFP-LC3 autophagosomes per cell. (C) Percentage of total EGFP-LC3 tracks longer than 1.5 μm. (D) Percentage of autophagosomes with mean speeds > 0.1 μm/s. (E) Percentage of autophagosomes with displacement > 2 μm in mock-transfected or ApoE2-, ApoE3-, or ApoE4-expressing RPE treated with or without A2E. Mean ± SEM, n > 13 cells per condition. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001. (B–E) One-way ANOVA with Bonferroni’s posttest. See also Supplemental Figure 2 and Supplemental Videos 1–8.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts